All News

exhibitor.floor.ACR

EULAR 2022 – Day 4 Report

d Jack Cush, MD

Bags are packed, ready to go, but wait there’s more abstracts to show.



The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest of study data often is showcased. 

Read Article
Axial Spondyloarthritis

Update on Axial SpA at EULAR 2022

d Antoni Chan, MD, PhD

This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference.

Read Article
cancer search news magnify

Malignancy risk on b/tsDMARDs in patients with prior malignancy history

d Eric Dein, MD

For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern.

Read Article
ice cubes

Topical therapies take centre stage

d Richard Conway, MBBChBAO, PhD

Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium. 

Read Article
gout.MTP1_.jpg

Real World Data on Urate Lowering Therapy

d Eric Dein, MD

Urate lowering therapy (ULT) is the backbone therapy for long-term gout treatment and maintenance, but real-world gout management is often imperfect and suboptimal. 

Read Article
PSA2L.jpg

Key Psoriatic Arthritis topics and updates at EULAR 2022

d Antoni Chan, MD, PhD

At EULAR 2022, I have been looking at topics and presentations in psoriatic arthritis (PsA).  Here are my top picks from this year's meeting.

Read Article
#EULAR2022 – Day 4 Report Check out our my favorite late-breakers from Day 4. https://t.co/R0hPetOos4 https://t.co/T57XRIKZs5

Links:

Dr. John Cush RheumNow ( View Tweet)
Spondyloarthritis and COVID-19 With the availability of vaccines and new therapeutics, many of our patients are fully vaccinated. We know this can limit their chances of severe COVID all while allowing their rheumatic disease to be treated. #EULAR2022 https://t.co/PmQNKYg1Ao https://t.co/N4DJVYJqrL

Links:

Dr. John Cush RheumNow ( View Tweet)
WATCH: Not Your Kind of RA Dr. David Liew discusses abstract OP0035 presented at #EULAR2022 Background: It has been suggested that rheumatoid arthritis (RA) starts at a younger age in cities with a lower latitude (closer to both sides of the equator). https://t.co/0l8b95emkn https://t.co/2leBR1nOBJ

Links:

Dr. John Cush RheumNow ( View Tweet)
#Bestinclass. #Giantcellarteritis GCA lots of novel ideas. V short prednisone- 2 months with #Tocilizumab. Not RCT. Looked safe & effective but too small to know if blindness etc are increased. Don’t suggest you try this at home...yet! @RheumNow @eular_org #EULAR2022 OP0185

Janet Pope Janetbirdope ( View Tweet)

#Bestinclass Recurrent #PMR RCT of #sarilumab v placebo. Nearly doubles sustained remission but maybe attenuating effect - flare difference over time? N=118. 🤷‍♀️ Dunno who I would use it in yet. LB0006 @RheumNow @eular_org #EULAR2022

Janet Pope Janetbirdope ( View Tweet)

Positive study NUT when to use the Rx? PMR RCTof 1 g #rituximab once. Over 1 yr with more steroid free remission - curves separate by 21 weeks (steroids off) POS0269 @RheumNow @eular_org #EULAR2023 when to use it-COVID risk, ?prefer IL6i

Janet Pope Janetbirdope ( View Tweet)

ARIAA: saw 18m results #EULAR2022 (alluded to at #ACR21) High-risk ACPA+ clinically suspect arthralgias Didn't progress to arthritis: after 6m abatacept: 92% vs 65% 12m after abatacept stopped: 65% vs 43% (tighter at points) How to pick those that benefit? POS0531 @RheumNow https://t.co/dkf1jU5gx7

Links:

David Liew drdavidliew ( View Tweet)

As #EULAR2022 comes to an end, there is still the playback that I am looking forward to watch. Here are my key Psoriatic Arthritis topics and updates from EULAR 2022 https://t.co/KNGGUJuukg @RheumNow

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)

WATCH: #EULAR2022 - Day 3 Faculty Panel Recap Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022. https://t.co/ExCXY6Xbl4 @Janetbirdope @AurelieRheumo @Yuz6Yusof https://t.co/tIB8QrdYuI

Links:

Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib: TYK2 inhibitor in pts with active SLE Phase 2, randomized, double blind, placebo-controlled study Met primary endpoint SRI response across all doses No death, MACE, VTE, systemic infections @RheumNow #EULAR2022 ABST#LB0004 https://t.co/yAM8qUZgee
Robert B Chao, MD doctorRBC ( View Tweet)
Sarilumab in pts with relapsing PMR - Phase 3 trial Sarilumab +14 week steroid taper - higher sustained Remission than w/o sarilumab (28% vs 10%) Less flare occurrences Sarilumab noted to have higher incidences of neutropenia, arthralgia @RheumNow #EULAR2022 ABST#LB0006 https://t.co/SeetkBsYI3
Robert B Chao, MD doctorRBC ( View Tweet)
Witholding MTX after both doses or only after the second dose of ChAdOx1 vaccine yields higher antibody repsonse compared to continuing MTX. Witholding MTX after second dose reduced the risk for flare. Data from MIVAC 1 and 2 #EULAR2022 @RheumNow LB https://t.co/GfL4eDXchb
Dr. Antoni Chan synovialjoints ( View Tweet)
In bDMARD-naive patients with PsA, the 24 week efficacy and safety of BKZ in BE OPTIMAL LB0001 by McInnes et al. At Week 16 ACR50 44% BKZ, 10% PBO, ADA 46%. PASI 90 at Week 16, 62% BKZ, PBO 3%, ADA 41% and benefit continued to Week 24 #EULAR2022 @RheumNow https://t.co/LRZoxzM57J
Dr. Antoni Chan synovialjoints ( View Tweet)
Great visual on how #socialmedia can further research and medical education #eular2022 @rheumnow @UnaMakris @UTSWRheum https://t.co/3OiQ6CggnA

Links:

TheDaoIndex KDAO2011 ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×